Electromed, Inc. (ELMD)

Electromed, Inc. experienced a share price decline of 12.30% between January 6, 2025, and January 2, 2026. On March 10, 2025, the board authorized a stock repurchase plan of $5,000,000. The company reported strong Q1 2026 financial results on November 13, 2025, leading to a 3.8% share gain the next day. The stock's composite rating was upgraded to 96 in December 2025, and Electromed entered a new senior secured revolving credit facility on December 18, 2025. The Q4 2025 earnings announcement on August 26, 2025, was followed by a 19.9% increase in share price.

Electromed, Inc. exhibits some demand seasonality, with historical data suggesting that October historically favors a long bias for the stock. The next statistically strong window for seasonality is anticipated to culminate around November 30, 2025.

Electromed, Inc. is a medical device company specializing in airway clearance therapy, operating within the Electromedical & Electrotherapeutic Apparatus and Medical Instruments industries. Founded in 1992, the company develops, manufactures, markets, and sells products designed to provide airway clearance therapy to patients with compromised pulmonary function. Its flagship product, the SmartVest® Airway Clearance System, utilizes High-Frequency Chest Wall Oscillation (HFCWO) technology to loosen and mobilize mucus in the airways. Electromed's products are used in the home healthcare market and hospitals, and include the SmartVest SQL® and SmartVest Clearway® models, as well as single-patient use SmartVest and SmartVest Wrap products for acute care settings.

Electromed, Inc. is headquartered in New Prague, Minnesota, USA, and operates manufacturing and distribution facilities within the United States. The company has a growing international customer base, with sales conducted through independent distributors in regions including Europe, the Arab states of the Persian Gulf, Southeast Asia, South America, and Central America.

Electromed, Inc. has maintained a positive brand reputation, characterized by consistent financial performance and positive analyst sentiment. The company has achieved its eighth consecutive quarter of year-over-year revenue and profit growth as of Q1 FY2025, and its tenth consecutive period of year-over-year revenue and net income growth as of Q3 FY2025. Electromed is recognized for the efficacy of its products and patient adherence in the HFCWO market, and analysts have a "Strong Buy" consensus rating for the stock. Potential challenges include margin compression, competitive headwinds, reduced sales representative productivity, and delays in developing new growth drivers.

Electromed, Inc. has a diverse ownership structure, including institutional shareholders, company insiders, and retail investors. Institutional shareholders hold approximately 46.76% of the company, while Electromed insiders own about 102.54%, and retail investors hold 0.00% according to one source. Another source indicates approximately 28.52% institutional investors, 7.16% insiders, and 64.32% public companies and individual investors. A third source states 52% institutions, 21.4% individual insiders, and 26.6% general public. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., and Renaissance Technologies Llc. Red Oak Partners LLC is the largest individual shareholder, owning 34.13% of the company.